<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04863664</url>
  </required_header>
  <id_info>
    <org_study_id>MDT19004</org_study_id>
    <nct_id>NCT04863664</nct_id>
  </id_info>
  <brief_title>Lead EvaluAtion for Defibrillation and Reliability (LEADR)</brief_title>
  <official_title>Lead EvaluAtion for Defibrillation and Reliability (LEADR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to assess the safety and efficacy of the Next Generation ICD lead.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enroll subjects who are indicated to receive an implantable single or dual&#xD;
      chamber ICD, or CRT-D and who meet all of the inclusion criteria and none of the exclusion&#xD;
      criteria. Subjects will receive an investigational Next Generation ICD Lead. Subjects will be&#xD;
      followed for at least 18 months following Next Generation ICD Lead implantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate the rate of major Lead complication-free rate at 6 months</measure>
    <time_frame>Implant to 6 Months</time_frame>
    <description>Subjects free of Next Generation ICD lead-related complication at 6 months post-implant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects successfully defibrillated at implant with the Next Generation ICD lead</measure>
    <time_frame>Day 1</time_frame>
    <description>Defibrillation testing will be completed in a subset of subjects at implant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate the fracture-free rate of the Next Generation ICD lead</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Subjects will be assessed at certain time points for Next Generation ICD lead fracture related to the Next Generation ICD lead.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Tachyarrhythmia</condition>
  <arm_group>
    <arm_group_label>Intervention/Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be implanted with a Next Generation ICD Lead and undergo required electrical testing</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Defibrillation</intervention_name>
    <description>Required electrical testing for pacing, sensing, impedance and defibrillation will be completed</description>
    <arm_group_label>Intervention/Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject meets current clinical practice guidelines for implantation of ICD or CRT-D&#xD;
             and will undergo one of the following:&#xD;
&#xD;
               -  de novo Medtronic CRT-D system implant&#xD;
&#xD;
               -  de novo Medtronic ICD system implant (single or dual chamber)&#xD;
&#xD;
          -  Subject has, per local law and requirements, the minimum age for autonomously signing&#xD;
             an ICF&#xD;
&#xD;
          -  Subject is willing to undergo implant defibrillation testing if requested.&#xD;
&#xD;
          -  Subject is geographically stable and willing and able to complete the study procedures&#xD;
             and visits for the duration of the follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is unwilling or unable to personally provide Informed Consent.&#xD;
&#xD;
          -  Subject has contraindications for standard RV transvenous lead placement (e.g.,&#xD;
             mechanical right heart valve).&#xD;
&#xD;
          -  Subject is contraindicated for â‰¤1 mg dexamethasone acetate.&#xD;
&#xD;
          -  Subject has a life expectancy of less than 12 months&#xD;
&#xD;
          -  For subject undergoing defibrillation testing the following medical conditions exclude&#xD;
             them:&#xD;
&#xD;
               -  Pre-existing or suspected pneumothorax during implant&#xD;
&#xD;
               -  Current intracardiac left atrial or left ventricular (LV) thrombus&#xD;
&#xD;
               -  Severe aortic stenosis&#xD;
&#xD;
               -  Severe proximal three-vessel or left main coronary artery disease without&#xD;
                  revascularization&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Ejection Fraction less than 25%&#xD;
&#xD;
               -  Recent stroke or transient ischemic attack (within the last 6 months)&#xD;
&#xD;
               -  Known inadequate external defibrillation&#xD;
&#xD;
               -  Any other known medical condition not listed that precludes their participation&#xD;
                  in the opinion of the investigator&#xD;
&#xD;
          -  Subject is enrolled or planning to enroll in a concurrent clinical study that may&#xD;
             confound the results of this study, without documented pre-approval from a Medtronic&#xD;
             study manager.&#xD;
&#xD;
          -  Subject with any exclusion criteria as required by local law (e.g., age or other).&#xD;
&#xD;
          -  Pregnant women or breastfeeding women, or women of childbearing potential and who are&#xD;
             not on a reliable form of birth regulation method or abstinence&#xD;
&#xD;
          -  Subject with an existing pacemaker (including transcatheter pacing system), ICD, or&#xD;
             CRT device or leads&#xD;
&#xD;
          -  Subject with any evidence of active infection or undergoing treatment for an infection&#xD;
&#xD;
          -  Recent (or planned) cardiac surgery or stenting less than 1 month before implant&#xD;
&#xD;
          -  End stage renal disease&#xD;
&#xD;
          -  Subjects with NYHA IV classification&#xD;
&#xD;
          -  Subjects with a transplanted heart&#xD;
&#xD;
          -  Subjects with previously extracted leads&#xD;
&#xD;
          -  Subjects with Left Ventricular Assist Device&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Crossley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nonye Harcourt</last_name>
    <phone>6122421785</phone>
    <email>nonye.o.harcourt@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keith Holloman</last_name>
    <phone>6126707136</phone>
    <email>keith.holloman@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lourdes Cardiology Services</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marisa Brown</last_name>
      <email>mbrown3@virtua.org</email>
    </contact>
    <investigator>
      <last_name>Darius Sholevar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Shore University Hospital</name>
      <address>
        <city>Bay Shore</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Shannon</last_name>
      <email>bshannon@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Chinitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TriHealth Hatton Research Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Freel</last_name>
      <email>laurie_freel@trihealth.com</email>
    </contact>
    <investigator>
      <last_name>Marshall Winner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Medical Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hollis Phillips</last_name>
      <email>hp9r@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Pamela Mason</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beevors Estelle</last_name>
      <email>estelle.beevors@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Denman Russell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide</name>
      <address>
        <city>Norwood</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Lyrtzis</last_name>
      <email>ellen.lyrtzis@adelaide.edu.au</email>
    </contact>
    <investigator>
      <last_name>Prashanthan Sanders</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Canberra Hospital</name>
      <address>
        <city>Garran</city>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Krepysheva</last_name>
      <email>olga.krepysheva@canberraheartrhythm.com.au</email>
    </contact>
    <investigator>
      <last_name>Rajeev Pathak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kar Wai Lee</last_name>
      <email>kkeikwai@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ngai-Yin Chan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ka Yee Alice Chan</last_name>
    </contact>
    <investigator>
      <last_name>Hung-Fat Tse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Sofie Ellekilde</last_name>
      <email>anne-sofie.ellekilde@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Berit Thornvig Philbert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jantung Negara - National Heart Institute</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amirah Nadiah Binti Zulkefli</last_name>
      <email>amirahnadiah@ijn.com.my</email>
    </contact>
    <investigator>
      <last_name>Surinder Kaur Khelae</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>China</country>
    <country>Denmark</country>
    <country>Malaysia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

